Plaintiff Firms Urge Inovio Investors to Seek Lead Role in Securities Suit by April 7

Overview

• Notices from the Schall Law Firm and DJS Law Group on February 23 invite investors to pursue lead-plaintiff positions before the April 7, 2026 deadline.
• The filed class action alleges violations of Sections 10(b) and 20(a) and SEC Rule 10b-5 through false or misleading statements.
• Claims focus on CELLECTRA manufacturing deficiencies that were likely to delay the INO-3107 BLA and on insufficient evidence for FDA priority or accelerated review.
• The proposed class covers purchasers of Inovio securities from October 10, 2023 through December 26, 2025, and the class has not been certified.
• Context from December 29, 2025: the FDA accepted the INO-3107 BLA for standard review rather than accelerated, and Inovio’s shares fell about 24% that day.